Abstract

Ciba have pointed out to us that there is no regulation in Norway reserving rifampicin for the treatment of tuberculous infections, as we had stated. In fact, to reduce the chance of drug resistant organisms emerging, Ciba has deliberately refrained from recommending the use of its drug for other purposes in Norway.